The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

iOnctura has begun a randomized phase 1/2 study investigating its lead asset, roginolisib, in combination with dostarlimab, ...

UCB has announced that its developmental treatment DoxTM, a combination of doxecitine and doxribtimine, has been granted ...

The Americas Awards are excited to introduce a new category, Clinical Trial Administrator. This category is designed to ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) have launched COMET, a programme designed to enhance early ...

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency (EMA) to extend the marketing authorisation for RYBREVANT (amivantamab) with ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

NICE reviewed various technologies and recommended DERM as the only AI tool suitable for NHS use. It is the first dermatology ...